EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

Translational Breast Cancer Research

ISSN 2218-6778 · AME Publishing Company

Latest articles

  1. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy

    Xiaojia Wang, Wei Li, Yongmei Yin, Zhongsheng Tong, Qingyuan Zhang, Hong Zheng, Zhimin Shao, Huiping Li, Jin Yang, Jifeng Feng, Fan Wu, Francois Lamour, Eleonora Restuccia, Zefei Jiang

    Published: 2023-01DOI: 10.21037/tbcr-23-2

Volumes

2026 · 332025 · 412024 · 362023 · 372022 · 382021 · 342020 · 30

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.